Atlas FDA

ADVIA Centaur Anti-HBc Total (HBcT2) and Atellica IM Anti-HBc Total (HBcT2)

FDA premarket approval P210019 · decided 2022-07-27

Approval details

PMA number
P210019
Trade name
ADVIA Centaur Anti-HBc Total (HBcT2) and Atellica IM Anti-HBc Total (HBcT2)
Generic name
Qualitative and Quantitative Hepatitis B Virus Antibody assays
Applicant
Siemens Healthcare Diagnostics, Inc.
Date received
2021-05-11
Decision date
2022-07-27
Days to decision
442 days
Decision code
APRL
Product code
SEI
Advisory committee
Microbiology
Expedited review
No
Location
Tarrytown, NY
Statement
Approval for the ADVIA Centaur® HBc Total 2 (HBcT2) assay. The ADVIA Centaur HBc Total 2 (HBcT2) assay is an in vitro diagnostic immunoassay for use in the qualitative determination of total antibodies to the core antigen of the hepatitis B virus (HBV) in human adult serum and plasma (EDTA, lithium heparin, and sodium heparin) using the Approval for the ADVIA Centaur XP and ADVIA Centaur XPT systems.This assay can be used as an aid in the diagnosis of adults with acute or chronic hepatitis B vir

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Atellica CH Acetaminophen 2 (ACTM) (K261364)Siemens Healthcare Diagnostics, Inc.2026-07-24
Atellica CH Diazo Total Bilirubin (D_TBil) (K251998)Siemens Healthcare Diagnostics, Inc.2026-02-27
Atellica® IM TSH3-Ultra II (TSH3ULII) (K251543)Siemens Healthcare Diagnostics, Inc.2026-02-06
Atellica IM Total PSA II (tPSAII) (K251630)Siemens Healthcare Diagnostics, Inc.2026-01-05
ADVIA Centaur Anti-Thyroglobulin II (aTgII) (K250816)Siemens Healthcare Diagnostics, Inc.2025-12-04
ADVIA Centaur Anti-Thyroid Peroxidase II (K250250)Siemens Healthcare Diagnostics, Inc.2025-10-17
Atellica IM Thyroglobulin (Tg) (K242981)Siemens Healthcare Diagnostics, Inc.2025-06-20
Atellica® CH Creatinine_3 (Crea3) (K242685)Siemens Healthcare Diagnostics, Inc.2024-12-04